🔗 Share this article

Given that the United States undertakes sweeping revisions to its immunization guidelines, one figure has emerged unexpectedly: Høeg, a US-based physician and public health researcher who first made her name by casting doubt on COVID-19 shots in the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her brief position at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials planned to reveal sweeping changes to the childhood vaccine schedule in December, aligning the US with Denmark’s immunization schedule, sources say – a major change that would place the US at odds with a large portion of the world with little proof for public health gain. The planned update has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics branches as Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has little discernible background in drug development, approval processes or leadership, which has been customary for former heads of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Past directors of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the kind of background that prior appointees who ran CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner stated.

“Everybody just pays attention on the novel medication approvals, but the generic program approves a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and each of these have to be supervised,” Dr. Woodcock explained. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the job, which manages in excess of 5,000 staff members. “It is a enormous management job, if you execute it properly,” she said.

Agency Reaction and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this selection signifies more teamwork among agency officials on immunizations, a representative stated that the “questions are based on incorrect presumptions”.

“This background aligns with the functions of her role,” the official stated, noting the time Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a contentious one-day drug-approval program that apparently concerned her former heads. “How are these therapies being selected for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

In general, he stated, “the FDA seems to be moving towards less stringent rules of all drugs, with the exception of immunizations.”

Established Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, history, some experts have noted. She authored a analysis using unconfirmed volunteer-provided data to estimate the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the new government included changing regulations for novel immunizations and discontinuing “non-essential” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing teenage boys from getting COVID-19 vaccinations.

“She’s an thorough dogmatist who begins with her beliefs and reverse-engineers to retrofit the data in a extremely misleading, fraudulent fashion,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|